Barclays Maintains Overweight on Teladoc Health, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Steve Valiquette maintains an Overweight rating on Teladoc Health and raises the price target from $10 to $12.
October 31, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Steve Valiquette has maintained an Overweight rating on Teladoc Health and increased the price target from $10 to $12, indicating a positive outlook on the stock.
The increase in price target from $10 to $12 by Barclays suggests a positive outlook on Teladoc Health's future performance. The Overweight rating indicates that the analyst expects the stock to outperform the market. This is likely to have a positive short-term impact on the stock price as investors may view this as a vote of confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100